乳腺癌新辅助治疗后乳腺病理完全缓解与腋窝淋巴结无转移的相关性
该研究基于荷兰癌症登记处2010-2016年接受新辅助全身治疗(NST)后手术的cT1-3N0-1乳腺癌患者,分析乳腺病理完全缓解(pCR)与最终病理腋窝淋巴结无转移(ypN0)的相关性。结果显示,cN0患者中乳腺pCR者97.7%为ypN0,cN1患者中乳腺pCR者45.0%为ypN0,乳腺pCR与ypN0独立相关(OR 4.53)。
要点
- cN0患者乳腺pCR后ypN0达97.7%,支持前瞻性试验探索豁免腋窝手术。
- cN1患者乳腺pCR后ypN0仅45.0%,不宜简单省略腋窝分期。
- 乳腺pCR与ypN0独立相关(OR 4.53, 95%CI 3.27-6.28)。
核心结论
- NST后乳腺pCR与cN0患者ypN0强相关,尤其在ER+HER2+、ER-HER2+和三阴性亚型中。
- 结果为未来临床试验在影像引导组织取样确认乳腺pCR后安全省略腋窝手术提供依据。
研究设计与样本
- 基于荷兰癌症登记处的回顾性队列研究,纳入2010-2016年cT1-3N0-1乳腺癌接受NST后手术的患者。
- 共纳入4084例患者,比较原发肿瘤病理缓解与腋窝病理结局,多变量分析确定与ypN0相关的临床病理变量。
主要发现
- 986例(24.1%)达到乳腺pCR。
- cN0患者中,乳腺pCR者97.7%(432/442)为ypN0,无pCR者71.6%(882/1232)为ypN0(P<0.001)。
- cN1患者中,乳腺pCR者45.0%(245/544)为ypN0,无pCR者9.4%(176/1866)为ypN0(P<0.001)。
- ypN0的 odds 在临床T3期(OR 0.59, 95%CI 0.40-0.87)、cN1(OR 0.03, 95%CI 0.02-0.04)和ER+HER2-亚型(OR 0.30, 95%CI 0.20-0.44)中降低,在乳腺pCR(OR 4.53, 95%CI 3.27-6.28)中升高。
临床怎么用
- cN0患者若乳腺pCR,腋窝淋巴结转移风险极低,可考虑参与临床试验评估豁免腋窝手术。
- cN1患者乳腺pCR后仍有较高腋窝转移风险,目前不宜常规省略腋窝手术。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The aim was to investigate whether pathologic complete response (pCR) in the breast is correlated with absence of axillary lymph node metastases at final pathology (ypN0) in patients treated with neoadjuvant systemic therapy (NST) for different breast cancer subtypes. BACKGROUND: Pathologic complete response rates have improved on account of more effective systemic treatment regimens. Promising results in feasibility trials with percutaneous image-guided tissue sampling for the identification of breast pCR after NST raise the question whether breast surgery is a redundant procedure. Thereby, the need for axillary surgery should be reconsidered as well. METHODS: Patients diagnosed with cT1-3N0-1 breast cancer and treated with NST, followed by surgery between 2010 and 2016, were selected from the Netherlands Cancer Registry. Patients were compared according to the pathologic response of the primary tumor with associated pathologic axillary outcome. Multivariable analysis was performed to determine clinicopathological variables correlated with ypN0. RESULTS: A total of 4084 patients were included for analyses, of whom 986 (24.1%) achieved breast pCR. In clinically node negative patients (cN0), 97.7% (432/442) with breast pCR had ypN0 compared with 71.6% (882/1232) without breast pCR (P < 0.001). In clinically node positive patients (cN1), 45.0% (245/544) with breast pCR had ypN0 compared with 9.4% (176/1866) without breast pCR (P < 0.001). The odds of ypN0 was decreased in case of clinical T3 stage (OR 0.59, 95% CI 0.40-0.87), cN1 (OR 0.03, 95% CI 0.02-0.04) and ER+HER2- subtype (OR 0.30, 95% CI 0.20-0.44), and increased in case of breast pCR (OR 4.53, 95% CI 3.27-6.28). CONCLUSIONS: Breast pCR achieved after NST is strongly correlated with ypN0 in cN0 patients, especially in ER+HER2+, ER-HER2+, and triple negative subtypes. These results provide data to proceed with future clinical trials to investigate if axillary surgery can be safely omitted in these selected patients when image-guided tissue sampling identifies a breast pCR.
引用
- Samiei S, van Nijnatten TJA, de Munck L, et al. Correlation Between Pathologic Complete Response in the Breast and Absence of Axillary Lymph Node Metastases After Neoadjuvant Systemic Therapy. Ann Surg. 2020. PMID: 30557203. doi:10.1097/SLA.0000000000003126
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。